| http://www.w3.org/ns/prov#value | - compliance with the FDA's GCP, or EU legislation governing GCP, including the failure to pass FDA, EMA or EU Member State inspections of clinical trials; ?? the FDA or other regulatory agencies may change their approval policies or adopt new regulations; ?? adverse medical events during the trials could lead to requirements that trials be repeated or extended, or that a program be
|
